Wedbush restated their outperform rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a report published on Wednesday morning, Benzinga reports. The firm currently has a $36.00 price objective on the stock. CGEM has been the topic of several other research reports. HC Wainwright reissued a buy rating and issued a $28.00 price […]

Piper Sandler reiterated their overweight rating on shares of CrowdStrike (NASDAQ:CRWD – Free Report) in a research report released on Thursday, Benzinga reports. The firm currently has a $290.00 target price on the stock. A number of other research analysts also recently issued reports on the stock. Argus reduced their price target on shares of […]

Progyny (NASDAQ:PGNY – Free Report) had its target price lowered by Cantor Fitzgerald from $37.00 to $25.00 in a report issued on Thursday, Benzinga reports. The firm currently has an overweight rating on the stock. Other equities analysts have also issued reports about the stock. Leerink Partners dropped their price objective on shares of Progyny […]

Susquehanna reiterated their positive rating on shares of CrowdStrike (NASDAQ:CRWD – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $310.00 target price on the stock. CRWD has been the topic of a number of other reports. Scotiabank dropped their price objective on CrowdStrike from $300.00 to $265.00 and […]

SS&C Technologies (NASDAQ:SSNC – Free Report) had its target price boosted by Needham & Company LLC from $81.00 to $90.00 in a research note issued to investors on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the technology company’s stock. SSNC has been the topic of several other reports. DA Davidson […]

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a neutral rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st. Get Our […]

JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) from an overweight rating to a neutral rating in a research note published on Thursday morning, Marketbeat Ratings reports. The firm currently has $57.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $52.00. HALO has been […]

Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its target price boosted by Oppenheimer from $14.00 to $15.00 in a research note published on Tuesday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. A number of other equities research analysts have also recently issued reports on CAPR. Maxim Group reaffirmed […]

LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a neutral rating to a buy rating in a research report report published on Monday morning, MarketBeat Ratings reports. The firm currently has $5.00 price objective on the stock. A number of other research analysts also recently issued reports on the stock. […]

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock […]

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a $21.00 price target on the stock. Several other brokerages have also recently commented on PDSB. B. Riley decreased their price target on shares of […]

JMP Securities initiated coverage on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $64.00 target price on the stock. Separately, Needham & Company LLC reiterated a buy rating and set a $55.00 target price on shares […]

Robert W. Baird upgraded shares of LivaNova (NASDAQ:LIVN – Free Report) from a neutral rating to an outperform rating in a report published on Tuesday morning, MarketBeat Ratings reports. Robert W. Baird currently has $66.00 target price on the stock, up from their previous target price of $55.00. Several other equities research analysts have also […]

Needham & Company LLC reiterated their buy rating on shares of Lattice Semiconductor (NASDAQ:LSCC – Free Report) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $61.00 price objective on the semiconductor company’s stock. LSCC has been the topic of a number of other research reports. Rosenblatt Securities reaffirmed […]

StockNews.com lowered shares of Nexstar Media Group (NASDAQ:NXST – Free Report) from a buy rating to a hold rating in a research report released on Tuesday morning. Other analysts have also issued reports about the company. Benchmark restated a buy rating and issued a $225.00 target price on shares of Nexstar Media Group in a […]

StockNews.com upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) to a sell rating in a research note released on Tuesday. Several other research firms have also recently weighed in on RGLS. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, […]

SS&C Technologies (NASDAQ:SSNC – Get Free Report) had its target price hoisted by stock analysts at Royal Bank of Canada from $75.00 to $86.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the technology company’s stock. Royal Bank of Canada’s target price […]

NIKE (NYSE:NKE – Get Free Report) had its price objective reduced by equities researchers at Sanford C. Bernstein from $112.00 to $109.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the footwear maker’s stock. Sanford C. Bernstein’s price target would suggest a potential upside of 25.94% […]